POLARIS INSIGHTS

Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?

Key PointsIts lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer.

More from the Markets desk